Skip to main
SHC

Sotera Health (SHC) Stock Forecast & Price Target

Sotera Health (SHC) Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 29%
Buy 57%
Hold 0%
Sell 14%
Strong Sell 0%

Bulls say

Sotera Health is positioned favorably because it is delivering consistent top-line beats across all three segments, with 2Q revenue of $321.4M, +8.0% cc, and 1Q revenue of $280.0M, +6.5% cc, while Sterigenics—the largest revenue driver—showed accelerating growth from pricing and volume/mix. Margin performance is also supporting the bullish view, as 2Q adjusted EBITDA margin reached 51.6% and adjusted EPS of $0.26 exceeded expectations, reinforcing management’s ability to convert demand strength into earnings growth. The outlook is further strengthened by higher 2026 guidance, led by revenue of +5.25-6.75% cc and adjusted EBITDA of +5.75-7.25% cc, plus continued litigation de-risking after the New Mexico case settlement and improving visibility in the remaining cases.

Bears say

Sotera Health is facing a less favorable valuation backdrop as peer group multiple compression in recent months has pushed the applied EV/EBITDA multiple down to 12x from 12.5x. The outlook also reflects a one-quarter roll-forward in the valuation framework against an NTM+1 EBITDA projection of $690M, implying limited upside from fundamentals alone. Despite its leading Sterigenics franchise and broad exposure to U.S. healthcare, pharmaceutical, and food safety demand, the company’s earnings multiple appears vulnerable to market de-rating.

Sotera Health (SHC) has been analyzed by 7 analysts, with a consensus rating of Buy. 29% of analysts recommend a Strong Buy, 57% recommend Buy, 0% suggest Holding, 14% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Sotera Health and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Sotera Health (SHC) Forecast

Analysts have given Sotera Health (SHC) a Buy based on their latest research and market trends.

According to 7 analysts, Sotera Health (SHC) has a Buy consensus rating as of Oct 24, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $21.71, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $21.71, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Sotera Health (SHC)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.